C 3 glomerulopathy (C3G) is a complement-mediated rare disease characterized by predominant glomerular C3 fragment deposition along with electron-dense deposits on electron microscopy. S1 Definitive diagnosis may be made by the microscopic evaluation of kidney biopsy samples; however, the causes that evoke complement dysregulation in individual cases have not yet been established.
The CFH gene encodes a key regulator of the complement pathway, the complement factor H (CFH). CFH and CFHR genes (CFHR1, 2, 3, 4, and 5), located adjacent to CFH, comprise the CFH/CFHR gene cluster on chromosome 1q32. These genes have high sequence homology, which makes the cluster capable of undergoing recombination events.
Six patterns of hybrid genes in the CFH/CFHR gene cluster were identified over the past few years; these included internal duplication of CFHR1, 1 CFHR5, 2,3 CFHR3-CFHR1 hybrid, 4 CFHR2-CFHR5 hybrid, 5 CFHR5-CFHR2 hybrid, 6 and CFHR1-CFHR5 hybrid. 7 A 15-year-old girl (III-1, Figure 1a ) presented with a history of recurrent macroscopic hematuria. A kidney biopsy revealed membranoproliferative glomerulonephritis ( Figure 1b ) with prominent C3 staining over the mesangial area ( Figure 1c ), but no relevant Ig staining. Electron microcopy showed subendothelial and intramembranous electron-dense deposits (Figure 1d and e). The patient's father (II-1) and her paternal aunt (II-3) had a history of proteinuria ( Figure 1a ). In both cases, light microscopy revealed membranoproliferative glomerulonephritis associated with prominent C3 staining (Figure 1f and g). They developed end-stage kidney disease and underwent hemodialysis.
In the index case (III-1), complement parameters C3, C4, and CH50 were within the normal range. Anti-CFH antibodies were not detected. The hemolytic assay using sheep red blood cells S2 showed that her plasma did not cause hemolysis.
A screen for pathogenic variants by Sanger sequencing detected no abnormality in CFH, CFI, CFB, C3, and MCP (see Supplementary Methods). Whole-exome sequencing performed to examine the C3G-associated genes, CFH, CFHR1-5, CFI, CFB, C3, and MCP, did not identify any pathogenic variants (see Supplementary Methods).
Western blotting of family members' plasma (see Supplementary Methods) for CFHR1 showed additional anomalous bands of approximately 40 kDa only in the affected members (II-1, II-3, and III-1) ( Figure 1h ). Western blot revealed that the CFHR2, 3, 4, and 5 proteins banded at their appropriate molecular weights in the blot (data not shown).
Copy number variation analysis in the CFH/CFHR gene cluster performed using multiplex ligationdependent probe analysis with commercial and inhouse probes (sequences available on request) showed an unusual heterozygous duplication extending from CFHR2 intron 1 to exon 3 only in the affected members (II-1, II-3, and III-1) ( Figure 1i ) (see Supplementary Methods). In addition, 4 family members (II-2, II-3, III-1, and III-2) had a classic CFHR3 and CFHR1 heterozygous deletion (⊿CFHR3/1), which was reportedly polymorphic. 8 Based on the Western blotting and multiplex ligation-dependent probe analysis results, we suspected the existence of a hybrid gene made up of CFHR1 and CFHR2. To identify chromosomal breakpoint, whole-genome analysis was performed using the genomic DNA sample of the patient's father (II-1) (see Supplementary Methods) . The software Breakdancer (version 1.3.6) 9,S3 detected a breakpoint between CFHR2 intron 3 and CFHR1 intron 1 (breakpoint B in Figure 1j ). A forward primer localized in CFHR2 intron 3 and a reverse primer in CFHR1 intron 1 generated an amplicon consistent with the breakpoint detected by Breakdancer (Figure 1k ). Based on the sequencing of the amplicon, we revealed the exact sequence around the breakpoint (Figure 1l ). Furthermore, the other breakpoint (breakpoint A in Figure 1j ), which was located on the opposite side of insertion, was characterized using the forward primer specific to the intergenic region between CFHR3 and CFHR1, and the reverse primer specific to CFHR2 intron 1 (Figure 1m ). Bidirectional sequencing of the amplicon revealed that the breakpoint was present within a 740-base pair (bp) region, homologous to sequences around CFHR1 exon 1 and CFHR2 exon 1.
Based on the results of Western blotting, showing that the patient and her paternal aunt do not have normal CFHR1 protein, but her father does, the hybrid gene should be on the other allele, where ⊿CFHR3/1 does not exist (Figure 1n ).
Overall, these data demonstrate that the disease segregated with a novel CFHR2-CFHR1 hybrid gene resulting from an in-flame insertion of 10,458-bp segment, which spans from CFHR2 exon1 to intron 3, into the 5ʹ side of CFHR1. The 5ʹ side of the insertion sequence was localized to a 740-bp homologous sequence. The aminoterminal duplicated CFHR protein (CFHR2 1,2 -CFHR1 hybrid protein) was predicted to exist (Figure 1o) .
The presence of multiple highly homologous sequences makes the CFH/CFHR gene cluster a hot spot for genomic rearrangement. S4 For example, ⊿CFHR3/1 is not rare in the general population (minor allele frequency 0.0-0.547, depending on the ethnicity S5 ). Most hybrid genes in the CFH/CFHR gene cluster are speculated to be the result of nonallelic homologous recombination; however, unlike ⊿CFHR3/1, the pathogenic hybrids in the CFH/ CFHR gene cluster were observed only in patients with C3G 1-7 or atypical hemolytic uremic syndrome. S6-S11 For the patients with C3G, the international conference recommended performing suitable methods to detect copy number variation or hybrid genes. 8 Our case also emphasizes the significance to perform such analyses. (i) C3G-affected members of the family, II-1, II-3, and III-1, carry heterozygous duplication of CFHR2 intron 1 to exon 3, which the healthy members, II-2 and III-2, do not. Four members in the family inherited the heterozygous deletion of CFHR3 and CFHR1 (DCFHR3/1). Multiplex ligation-dependent probe analysis for CFHR4 was performed with inhouse probes. (j) Schematic representation of the CFHR2-CFHR1 hybrid gene. A 10,458-bp CFHR2 sequence was inserted to the beginning of the CFHR1 gene. The 5ʹ region of insertion (breakpoint A) was in 740-bp homologous sequence, between the sequence around CFHR1 exon 1 and that around CFHR2 exon 1. In the present case, the 2 breakpoints displayed different characteristics. Breakpoint A occurred in the 740-bp homologous sequences, which indicates the occurrence of nonallelic homologous recombination. However, breakpoint B indicates the occurrence of nonhomologous end joining, due to the absence of homology. Moreover, the Breakdancer software could not detect the breakpoint A, whereas it could detect breakpoint B. Because Breakdancer provides a genomewide detection of structural variations using the information from "discordant read pairs," 9,S3,S12 it cannot detect the recombination between homologous sequences longer than the paired-end read (350 bp for HiSeq X).
The present CFHR2-CFHR1 hybrid protein and the C3G-associated hybrid proteins described in previous reports [1] [2] [3] [4] [5] [6] [7] share common characteristics, such as duplication of the N-terminal domain. Duplicated Nterminal domain may reportedly cause multimerization of the hybrid proteins, which increases their competition with CFH and causes dysregulation of the complement pathway. S13 To date, the standard treatment for C3G has not been established. Detailed genetic analysis is recommended to elucidate the pathophysiology of C3G and develop new treatment options.
To conclude, we have described a familial case of C3G with a novel CFHR2-CFHR1 hybrid gene. This is the first case of C3G-associated hybrid gene detection using whole-genome sequencing. As the hybrid gene originated from recombination between introns, it could not be detected by whole-exome sequencing or Sanger sequencing of the exons. Detailed examination of the CFH/CFHR gene cluster, such as structural variation analysis or copy number analysis, is required to determine the cause of familial cases of C3G with previously unknown etiology.
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